glp-1 obesity drugs news today There's been a 1,500% increase in poison control calls related to the overdose or side effects of weight-loss drugs. A woman describes a GLP -1 overdose that left her hospitalized New Research Uncovers Hidden Side

An effective treatment might require either utilization of multiple drugs which target the individual pathological processes which underlie the neurodegenerative disease or the use of a single agent which could influence multiple pathological processes

The fascinating history of the GLP-1 drugs- Ozempic, Wegovy, and Mounjaro.

Then, we will discuss the approaches that can increase the endogenous production of GLP-1 through various stimuli

Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers...

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D